PMVP (PMV Pharmaceuticals) Current Accrued Expense: $5.13 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PMVP PMV Pharmaceuticals Inc PMVP
32 GF Score
Price $1.29
! 2 Warning Signs
View Full Analysis

What is PMV Pharmaceuticals Current Accrued Expense?

PMV Pharmaceuticals PMVP +4.88% 32 Current Accrued Expense is $5.13 Mil as of Jun. 2026. GuruFocus rates PMVP with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

PMV Pharmaceuticals's Current Accrued Expense for the quarter that ended in Jun. 2026 was $5.13 Mil.

PMV Pharmaceuticals's quarterly Current Accrued Expense increased from Dec. 2025 ($3.33 Mil) to Mar. 2026 ($4.26 Mil) and increased from Mar. 2026 ($4.26 Mil) to Jun. 2026 ($5.13 Mil).

PMV Pharmaceuticals's annual Current Accrued Expense declined from Dec. 2023 ($5.44 Mil) to Dec. 2024 ($2.43 Mil) but then increased from Dec. 2024 ($2.43 Mil) to Dec. 2025 ($3.33 Mil).

PMV Pharmaceuticals Current Accrued Expense Related Terms

PMV Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for PMV Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PMV Pharmaceuticals Current Accrued Expense Chart

PMV Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 4.83 4.41 5.44 2.43 3.33

PMV Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.58 4.59 3.33 4.26 5.13
PMVP
32GF Score
PMV Pharmaceuticals Inc PMVP
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PMV Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $5.13 Mil mean?
PMV Pharmaceuticals (PMVP) has a Current Accrued Expense of $5.13 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on PMV Pharmaceuticals and its competitors.
Is PMV Pharmaceuticals' Current Accrued Expense too high?
PMV Pharmaceuticals' current Current Accrued Expense is $5.13 Mil. Overall, PMV Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PMV Pharmaceuticals' Current Accrued Expense compare to HYFT and INMB?
PMV Pharmaceuticals' Current Accrued Expense of $5.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on PMV Pharmaceuticals and its competitors. PMV Pharmaceuticals's current Current Accrued Expense is $5.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PMV Pharmaceuticals stock overvalued right now?
PMV Pharmaceuticals (PMVP) has a current Current Accrued Expense of $5.13 Mil. The current Current Accrued Expense is $5.13 Mil. PMV Pharmaceuticals' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For PMV Pharmaceuticals (PMVP), the current Current Accrued Expense is $5.13 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PMV Pharmaceuticals Business Description

Address 400 Alexander Park Drive, Suite 301, Princeton, NJ, USA, 08540
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
32GF Score

Get the complete analysis for PMVP

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.29
Price